CAMBRIDGE, Mass. , April 29, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

CAMBRIDGE, Mass. , April 15, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the

CAMBRIDGE, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

- Well tolerated at doses up to 43 mg/m 2 with encouraging activity in heavily pre-treated patient populations - Favorable trend towards higher response rates with higher NaPi2b expression - On track for interim disclosure of Phase 1 expansion cohort data in Q2 2020 CAMBRIDGE, Mass.

Conference call on Monday, March 30, 2020, at 5:00 p.m. ET featuring study investigator Debra L. Richardson, MD CAMBRIDGE, Mass. , March 20, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline

XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women’s Cancer XMT-1536 interim Phase 1 dose expansion data to be presented in 2Q 2020 with more mature data expected in 2H 2020 Company

CAMBRIDGE, Mass. , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

CAMBRIDGE, Mass. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

XMT-1536 On Track to Demonstrate Proof of Concept in Both Ovarian and Non-Small Cell Lung Cancer with Multiple Data Readouts Expected Throughout 2020 XMT-1536 Expansion Study Dose Increased; Dose Escalation Study Continues Next Clinical Candidate, XMT-1592, a Dolasynthen ADC Targeting NaPi2b, to

CAMBRIDGE, Mass. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. , (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that